Health
Health Canada approves RYBELSUS® (semaglutide tablets) to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes
Novo Nordisk announced today that Health Canada has approved RYBELSUS® (semaglutide tablets) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or are at high risk for these events.1,2
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"RYBELSUS® (semaglutide tablets) is the first glucagon-like peptide-1 (GLP-1) approved in Canada to reduce the risk of major adverse cardiovascular events (MACE).1","length":162,"tagName":"p"}]},{"val":[{"type":"text","content":"RYBELSUS® (semaglutide tablets) is approved to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or are at high risk for these events.1,2","length":295,"tagName":"p"}]},{"val":[{"type":"text","content":"The indication expansion is based on positive outcomes observed in the cardiovascular outcomes (SOUL) trial data, which demonstrated that RYBELSUS® decreased the risk of major adverse cardiovascular events.1","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"Cardiovascular disease is the second-leading cause of death in Canada.3","length":71,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":735,"olType":false},{"type":"text","content":"MISSISSAUGA, ON, Jan. 12, 2026 /CNW/ - Novo Nordisk announced today that Health Canada has approved RYBELSUS® (semaglutide tablets) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or are at high risk for these events.1,2","length":393,"tagName":"p"},{"type":"text","content":"In Canada, cardiovascular disease remains a public health challenge, with heart disease as the second leading cause of death and a leading cause of hospitalization.4 It's estimated that 9 in 10 Canadians have at least one risk factor for stroke, heart disease, or vascular cognitive impairment including: sex, age, diabetes, family history and Indigenous, South Asian and African family heritage.5","length":401,"tagName":"p"},{"type":"text","content":"Health Canada's approval of this indication is based on the results of the SOUL trial.2 Trial results confirmed that the risk of a major adverse cardiovascular event (MACE) decreased with the use of RYBELSUS® as compared to a placebo, when used concomitantly with standard of care treatments for diabetes and cardiovascular disease.1","length":337,"tagName":"p"},{"type":"i...